Recombinant Human G-protein coupled receptor 183 (GPR183)

What is GPR183 and what is its basic function in human biology?

GPR183, also known as Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2), is a seven-transmembrane receptor belonging to the G protein-coupled receptor family. This 361 amino acid protein functions primarily as a chemotactic receptor that binds to oxysterols, particularly 7α,25-dihydroxycholesterol (7a,25-OHC), mediating immune cell migration and positioning within tissues .

GPR183 plays a critical role in:

• Guiding immune cell migration in response to oxysterol gradients

• B cell positioning during germinal center reactions

• T cell trafficking and differentiation

• Embryonic hematopoietic stem and progenitor cell (HSPC) development

The receptor is highly expressed in lymphoid tissues and B-lymphocyte cell lines, but shows lower expression in T-lymphocyte cell lines and peripheral blood T lymphocytes .

Which cell types express GPR183 and at what levels?

GPR183 shows a diverse expression pattern across immune cell populations:

• Eosinophils: Uniformly high expression levels, consistently demonstrated in peripheral blood samples from both rhesus macaques and healthy humans

• B lymphocytes: High expression in peripheral B cells, which is downregulated when B cells enter germinal centers and upregulated again upon exit

• T lymphocytes: Variable expression, with elevated levels in specific subsets such as those expressing CCR6 or CCR9, and particularly in Th17 memory T cells

• Other immune cells: Expression detected in macrophages, dendritic cells, astrocytes, and innate lymphoid cells

Notably, GPR183 expression remains consistently high on eosinophils in tuberculosis granulomas while being negative on neutrophils in the same microenvironment .

What are the key differences between GPR183 and other chemotactic receptors?

GPR183 distinguishes itself from other chemotactic receptors in several important ways:

• Ligand specificity: Unlike classic chemokine receptors that bind peptide chemokines, GPR183 binds oxysterols (oxidized derivatives of cholesterol), particularly 7α,25-dihydroxycholesterol

• Expression pattern: While many chemotactic receptors show restricted cellular expression, GPR183 is expressed across multiple immune cell lineages, with particularly high expression on eosinophils

• Functional coordination: GPR183 can work in conjunction with other chemotactic receptors, as demonstrated by the additive migratory effect when both GPR183 and CCR6 are stimulated by their respective ligands (7α,25-dihydroxycholesterol and CCL20)

• Multifunctional signaling: Beyond chemotaxis, GPR183 activation can also amplify inflammatory transcriptional responses in macrophages and exhibit direct antiviral properties

How does the single nucleotide polymorphism rs9557195 affect GPR183 function and disease susceptibility?

The rs9557195 SNP within the GPR183 gene has significant functional and clinical implications:

• Surface expression: IBD patients carrying the CC allele of rs9557195 demonstrate higher GPR183 surface expression on blood lymphocytes compared to individuals with the TT allele

• Disease associations: This polymorphism has been linked to:

  • Increased risk for inflammatory bowel diseases (IBD)

  • Higher rates of psoriasis in IBD patients with the CC allele compared to those with the TT allele

• Functional consequences: The elevated GPR183 expression associated with the CC allele likely enhances immune cell migration to sites of inflammation, potentially exacerbating inflammatory conditions through increased recruitment of pro-inflammatory lymphocytes

• Mechanistic insights: The rs9557195 polymorphism appears to regulate GPR183 expression levels rather than altering the receptor's binding affinity or downstream signaling pathways, pointing to a quantitative rather than qualitative effect on receptor function

What is the significance of the MX2/GPR183 transcript ratio in infectious disease research?

The ratio between MX2 (an interferon response gene) and GPR183 transcripts has emerged as a significant biomarker in malaria vaccine research:

• Predictive value: The MX2/GPR183 transcript ratio, measured one day after the third immunization with the RTS,S malaria vaccine, consistently discriminates between protected and non-protected individuals across multiple studies and vaccine regimens

• Complementary biomarker: This transcript ratio provides information that is complementary to anti-CSP antibody titers, with statistically significant improvements in discrimination when combining both measurements (p = 0.005 and 0.003 for RRR and alternative vaccine regimens, respectively)

• Independence: Importantly, the MX2/GPR183 expression ratio does not correlate with anti-CSP antibody titers, suggesting these biomarkers capture distinct aspects of the vaccine-induced immune response

• Translational potential: This ratiometric approach could be developed into a molecular predictor of vaccine efficacy, potentially allowing for personalized vaccination strategies in malaria prevention

How does GPR183 expression change during tuberculosis infection and what are the implications?

GPR183 undergoes dynamic regulation during tuberculosis (TB) infection with significant implications for disease pathogenesis:

What are the optimal methods for measuring GPR183 expression in different research contexts?

Researchers have successfully employed several complementary approaches to measure GPR183 expression:

• Flow cytometry: The gold standard for measuring GPR183 protein expression at the single-cell level, allowing for precise quantification across different immune cell populations. This method has been successfully used to measure GPR183 levels on eosinophils in peripheral blood and tissue samples

• Western blotting: Effective for detecting total GPR183 protein in cell lysates, providing a semi-quantitative measure of expression levels

• Transcriptomics (RNA-Seq/microarray): Valuable for assessing GPR183 mRNA expression in complex tissue samples or at a population level, as demonstrated in studies examining GPR183 transcript levels in whole blood during TB infection

• Single-cell RNA sequencing: Provides high-resolution expression data at the individual cell level, allowing identification of GPR183-expressing cells within heterogeneous populations

• Proteogenomic approaches: Combined analysis of transcript and protein/phosphopeptide levels can reveal correlations between RNA and protein expression, as examined in breast cancer and hepatitis B-related hepatocellular carcinoma cohorts

What experimental models are most appropriate for studying GPR183 function?

Several experimental models have proven valuable for investigating different aspects of GPR183 biology:

• In vitro migration assays: Essential for studying GPR183-mediated chemotaxis in response to oxysterol gradients. These assays have demonstrated that GPR183 ligands and CCR6 ligands can stimulate migration of memory T cells in an additive manner

• GPR183 knockout mice: Valuable for determining the in vivo role of GPR183 in immune cell trafficking and during infection. Studies with Gpr183 -/- eosinophils have shown their reduced but not abolished ability to home to the lungs during Mycobacterium tuberculosis infection

• Rhesus macaque models: Provide a physiologically relevant model for studying GPR183 expression and function in TB granulomas, which more closely resemble human pathology than mouse models

• Human clinical samples: Critical for validating findings from animal models and establishing clinical relevance. Analysis of resected TB lung lesions and peripheral blood from pulmonary TB patients has revealed important insights about GPR183 expression patterns

• Cell-specific conditional knockout models: Allow investigation of GPR183 function in specific cell lineages without affecting other cell types, providing more precise mechanistic insights

How can researchers effectively manipulate GPR183 signaling in experimental settings?

Several strategies are available for modulating GPR183 activity to study its functional consequences:

• Genetic approaches:

  • CRISPR/Cas9-mediated knockout or knockin

  • siRNA/shRNA for transient knockdown

  • Overexpression systems using viral vectors

• Pharmacological tools:

  • 7α,25-dihydroxycholesterol (7α,25-OHC) as a potent natural agonist

  • Synthetic GPR183 agonists and antagonists

  • Inhibitors of cholesterol 25-hydroxylase (Ch25h), which produces the enzyme that generates GPR183 ligands

• Blocking experiments:

  • Anti-GPR183 neutralizing antibodies

  • Oxysterol scavengers to deplete ligands

• Downstream signaling modulation:

  • G-protein subunit inhibitors

  • Signaling pathway inhibitors targeting post-receptor events

These approaches have revealed that blocking GPR183 signaling attenuates hematopoietic stem and progenitor cell generation, while activating GPR183 signaling leads to increased functional HSPC production .

How should researchers interpret correlations between GPR183 expression and disease states?

When analyzing correlations between GPR183 expression and disease states, researchers should consider several key interpretative frameworks:

What are the key considerations when analyzing GPR183 genetic variants in population studies?

When studying GPR183 genetic variants across populations, researchers should account for:

• Allele frequency variations: Different populations may show distinct frequencies of GPR183 polymorphisms like rs9557195, which can influence disease association findings

• Linkage disequilibrium patterns: Determine whether the studied variant is causative or simply in linkage with the true functional variant

• Functional characterization: Experimentally validate how variants affect:

  • GPR183 expression levels (as seen with rs9557195's effect on surface expression)

  • Protein structure and ligand binding

  • Downstream signaling pathways

  • Cell migration and positioning

• Disease context specificity: A variant may be relevant in one disease context but not others. For instance, rs9557195 is associated with both IBD risk and psoriasis rates in IBD patients

• Interaction with environmental factors: Consider how genetic variants might interact with dietary, microbial, or other environmental factors that affect oxysterol levels

• Clinical outcomes correlation: Assess whether variants predict disease onset, progression, complications, or treatment response to establish clinical relevance

Data Tables and Research Findings

Based on current evidence, several therapeutic approaches targeting GPR183 show promise:

• Inflammatory bowel disease interventions: Given the association between GPR183 polymorphisms and IBD, targeted inhibition of GPR183 signaling could potentially reduce inflammatory cell recruitment to the intestine

• Tuberculosis immunotherapy: Modulating GPR183-mediated eosinophil recruitment might enhance early immune responses to Mycobacterium tuberculosis infection

• Vaccine response prediction: The MX2/GPR183 transcript ratio could be developed as a biomarker to identify individuals who may require additional vaccine doses or alternative formulations

• Precision medicine approaches: Genotyping GPR183 variants like rs9557195 could help stratify patients for targeted therapies based on their predicted inflammatory responses

• Combined receptor targeting strategies: Dual targeting of GPR183 with other chemotactic receptors (like CCR6) could provide synergistic benefits in controlling inflammatory cell migration

When pursuing these applications, researchers should carefully consider the context-dependent roles of GPR183 in different tissues and disease states to avoid unintended consequences.

What are the critical knowledge gaps in GPR183 biology that require further investigation?

Despite significant advances, several important aspects of GPR183 biology remain to be elucidated:

• Cell type-specific functions: While GPR183's role is well-characterized in B cells, its functions in other cell types, particularly eosinophils and innate immune cells, require further investigation

• Tissue-specific regulation: The mechanisms controlling GPR183 expression across different tissues and disease states are not fully understood

• Signaling pathways: The complete spectrum of downstream signaling events triggered by GPR183 activation and how these vary across cell types needs further characterization

• Non-chemotactic functions: Beyond chemotaxis, GPR183 may exhibit anti-microbial properties and modulate inflammatory transcriptional responses, which warrant deeper exploration

• Therapeutic targeting strategies: Development of selective GPR183 modulators with favorable pharmacological properties remains an important goal

• Integration with other migratory signals: How GPR183 signaling integrates with other chemotactic pathways to orchestrate complex cell migration patterns in health and disease needs further clarification